Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking
A group of 456 consecutive patients seen ≤ 6 h after the onset of acute myocardial infarction associated with ST segment elevation received thrombolytic therapy and were followed up for 12 months. Intravenous streptokinase was given to 315 patients and recombinant tissue-type plasminogen activator (...
Gespeichert in:
Veröffentlicht in: | Journal of the American College of Cardiology 1990-08, Vol.16 (2), p.340-348 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 348 |
---|---|
container_issue | 2 |
container_start_page | 340 |
container_title | Journal of the American College of Cardiology |
container_volume | 16 |
creator | Rivers, John T. White, Harvey D. Cross, David B. Williams, Barbara F. Norris, Robin M. |
description | A group of 456 consecutive patients seen ≤ 6 h after the onset of acute myocardial infarction associated with ST segment elevation received thrombolytic therapy and were followed up for 12 months. Intravenous streptokinase was given to 315 patients and recombinant tissue-type plasminogen activator (rt-PA) to 141 patients. Reinfarction rate and risk factors for reinfarction were assessed. Management after thrombolysis was conservative; revascularization procedures were reserved for patients with symptoms refractory to medical therapy or for those with left main coronary artery stenosis. Coronary artery surgery or angioplasty was performed in only 3.7% of patients during the first 30 days after thrombolysis and in only 8.6% by 1 year. Most patients (79%) underwent coronary arteriography.
Twenty-six patients (5.7%) exhibited signs of threatened reinfarction at 1 month after thrombolytic therapy as did 43 patients (9.4%) by 1 year. Reinfarction was prevented in four of these patients by early readministration of thrombolytic therapy. Multivariate analysis of possible risk factors for reinfarction identified at the time of initial infaction showed current cigarette smoking to be the only predictive factor (reinfarction occurred in 12.5% of smokers versus 6.3% of nonsmokers, p = 0.04). A second analysis of risk factors identified 3 weeks after initial infarction, including the severity of residual stenosis at coronary arteriography and exercise test variables, again showed continued cigarette smoking to be the only factor predictive of reinfarction. Twenty percent of patients who continued to smoke developed reinfarction compared with 5.1% of those who stopped (p < 0.01).
Conservative management after thrombolysis with streptokinase or rt-PA results in a reinfarction rate of 8.6% at 1 year. Cigarette smoking predisposes patients to reinfarction; cessation of smoking reduces the risk of reinfarction. The impact of threatened reinfarction can be limited by prompt readministration of thrombolytic therapy. |
doi_str_mv | 10.1016/0735-1097(90)90583-B |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_79894476</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>073510979090583B</els_id><sourcerecordid>79894476</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-ce6bdadfeb8fbc2dec9b0f9eef937a0e47a3c333dab5d0deca09cf3e044d9bc43</originalsourceid><addsrcrecordid>eNp9kdFqFDEUhoNY6lp9A4XcKHoxmtnM7Ey8EGzRtlAQRK_DmZOTGp1Jtkl2ZR6ir-ML-GJm3aV65VU4nO__Cd9h7EktXtWiXr0WnWyrWqjuhRIvlWh7WZ3eY4u6bftKtqq7zxZ3yAP2MKVvQohVX6tjdrysCyb7Bbv9RM5biJhd8Bxspsjz1xim4dfPcc4Oy0QR1jO3IXLATSY-zQEhGgcj_ydrwziGH2T4MHMMPlHcQnbbgoOHa5rI5zf80qMz5JE4eMPJWsLMg-VpCt-dv37EjiyMiR4f3hP25cP7z2cX1dXH88uzd1cVNn2XK6TVYMBYGno74NIQqkFYRWSV7EBQ04FEKaWBoTWirEEotJJE0xg1YCNP2PN97zqGmw2lrCeXkMYRPIVN0p3qVdN0qwI2exBjSCmS1evoJoizroXeXUHvFOudYq2E_nMFfVpiTw_9m2Eicxc6aC_7Z4c9JITRRihe0t9uJWXTL5eFe7vnqMjYOoo6odvpMy4Wc9oE9_-P_AZEx6pW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>79894476</pqid></control><display><type>article</type><title>Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Rivers, John T. ; White, Harvey D. ; Cross, David B. ; Williams, Barbara F. ; Norris, Robin M.</creator><creatorcontrib>Rivers, John T. ; White, Harvey D. ; Cross, David B. ; Williams, Barbara F. ; Norris, Robin M.</creatorcontrib><description>A group of 456 consecutive patients seen ≤ 6 h after the onset of acute myocardial infarction associated with ST segment elevation received thrombolytic therapy and were followed up for 12 months. Intravenous streptokinase was given to 315 patients and recombinant tissue-type plasminogen activator (rt-PA) to 141 patients. Reinfarction rate and risk factors for reinfarction were assessed. Management after thrombolysis was conservative; revascularization procedures were reserved for patients with symptoms refractory to medical therapy or for those with left main coronary artery stenosis. Coronary artery surgery or angioplasty was performed in only 3.7% of patients during the first 30 days after thrombolysis and in only 8.6% by 1 year. Most patients (79%) underwent coronary arteriography.
Twenty-six patients (5.7%) exhibited signs of threatened reinfarction at 1 month after thrombolytic therapy as did 43 patients (9.4%) by 1 year. Reinfarction was prevented in four of these patients by early readministration of thrombolytic therapy. Multivariate analysis of possible risk factors for reinfarction identified at the time of initial infaction showed current cigarette smoking to be the only predictive factor (reinfarction occurred in 12.5% of smokers versus 6.3% of nonsmokers, p = 0.04). A second analysis of risk factors identified 3 weeks after initial infarction, including the severity of residual stenosis at coronary arteriography and exercise test variables, again showed continued cigarette smoking to be the only factor predictive of reinfarction. Twenty percent of patients who continued to smoke developed reinfarction compared with 5.1% of those who stopped (p < 0.01).
Conservative management after thrombolysis with streptokinase or rt-PA results in a reinfarction rate of 8.6% at 1 year. Cigarette smoking predisposes patients to reinfarction; cessation of smoking reduces the risk of reinfarction. The impact of threatened reinfarction can be limited by prompt readministration of thrombolytic therapy.</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/0735-1097(90)90583-B</identifier><identifier>PMID: 2115538</identifier><identifier>CODEN: JACCDI</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Cardiac Catheterization ; Combined Modality Therapy ; Coronary Angiography ; Coronary Artery Bypass ; Creatine Kinase - blood ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Myocardial Infarction - mortality ; Myocardial Infarction - physiopathology ; Myocardial Infarction - therapy ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Recombinant Proteins - therapeutic use ; Recurrence ; Risk Factors ; Smoking - adverse effects ; Smoking - epidemiology ; Streptokinase - therapeutic use ; Survival Rate ; Thrombolytic Therapy ; Tissue Plasminogen Activator - therapeutic use</subject><ispartof>Journal of the American College of Cardiology, 1990-08, Vol.16 (2), p.340-348</ispartof><rights>1990</rights><rights>1991 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-ce6bdadfeb8fbc2dec9b0f9eef937a0e47a3c333dab5d0deca09cf3e044d9bc43</citedby><cites>FETCH-LOGICAL-c487t-ce6bdadfeb8fbc2dec9b0f9eef937a0e47a3c333dab5d0deca09cf3e044d9bc43</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/0735-1097(90)90583-B$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=19334822$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/2115538$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rivers, John T.</creatorcontrib><creatorcontrib>White, Harvey D.</creatorcontrib><creatorcontrib>Cross, David B.</creatorcontrib><creatorcontrib>Williams, Barbara F.</creatorcontrib><creatorcontrib>Norris, Robin M.</creatorcontrib><title>Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking</title><title>Journal of the American College of Cardiology</title><addtitle>J Am Coll Cardiol</addtitle><description>A group of 456 consecutive patients seen ≤ 6 h after the onset of acute myocardial infarction associated with ST segment elevation received thrombolytic therapy and were followed up for 12 months. Intravenous streptokinase was given to 315 patients and recombinant tissue-type plasminogen activator (rt-PA) to 141 patients. Reinfarction rate and risk factors for reinfarction were assessed. Management after thrombolysis was conservative; revascularization procedures were reserved for patients with symptoms refractory to medical therapy or for those with left main coronary artery stenosis. Coronary artery surgery or angioplasty was performed in only 3.7% of patients during the first 30 days after thrombolysis and in only 8.6% by 1 year. Most patients (79%) underwent coronary arteriography.
Twenty-six patients (5.7%) exhibited signs of threatened reinfarction at 1 month after thrombolytic therapy as did 43 patients (9.4%) by 1 year. Reinfarction was prevented in four of these patients by early readministration of thrombolytic therapy. Multivariate analysis of possible risk factors for reinfarction identified at the time of initial infaction showed current cigarette smoking to be the only predictive factor (reinfarction occurred in 12.5% of smokers versus 6.3% of nonsmokers, p = 0.04). A second analysis of risk factors identified 3 weeks after initial infarction, including the severity of residual stenosis at coronary arteriography and exercise test variables, again showed continued cigarette smoking to be the only factor predictive of reinfarction. Twenty percent of patients who continued to smoke developed reinfarction compared with 5.1% of those who stopped (p < 0.01).
Conservative management after thrombolysis with streptokinase or rt-PA results in a reinfarction rate of 8.6% at 1 year. Cigarette smoking predisposes patients to reinfarction; cessation of smoking reduces the risk of reinfarction. The impact of threatened reinfarction can be limited by prompt readministration of thrombolytic therapy.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Cardiac Catheterization</subject><subject>Combined Modality Therapy</subject><subject>Coronary Angiography</subject><subject>Coronary Artery Bypass</subject><subject>Creatine Kinase - blood</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Myocardial Infarction - mortality</subject><subject>Myocardial Infarction - physiopathology</subject><subject>Myocardial Infarction - therapy</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>Recurrence</subject><subject>Risk Factors</subject><subject>Smoking - adverse effects</subject><subject>Smoking - epidemiology</subject><subject>Streptokinase - therapeutic use</subject><subject>Survival Rate</subject><subject>Thrombolytic Therapy</subject><subject>Tissue Plasminogen Activator - therapeutic use</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1990</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kdFqFDEUhoNY6lp9A4XcKHoxmtnM7Ey8EGzRtlAQRK_DmZOTGp1Jtkl2ZR6ir-ML-GJm3aV65VU4nO__Cd9h7EktXtWiXr0WnWyrWqjuhRIvlWh7WZ3eY4u6bftKtqq7zxZ3yAP2MKVvQohVX6tjdrysCyb7Bbv9RM5biJhd8Bxspsjz1xim4dfPcc4Oy0QR1jO3IXLATSY-zQEhGgcj_ydrwziGH2T4MHMMPlHcQnbbgoOHa5rI5zf80qMz5JE4eMPJWsLMg-VpCt-dv37EjiyMiR4f3hP25cP7z2cX1dXH88uzd1cVNn2XK6TVYMBYGno74NIQqkFYRWSV7EBQ04FEKaWBoTWirEEotJJE0xg1YCNP2PN97zqGmw2lrCeXkMYRPIVN0p3qVdN0qwI2exBjSCmS1evoJoizroXeXUHvFOudYq2E_nMFfVpiTw_9m2Eicxc6aC_7Z4c9JITRRihe0t9uJWXTL5eFe7vnqMjYOoo6odvpMy4Wc9oE9_-P_AZEx6pW</recordid><startdate>19900801</startdate><enddate>19900801</enddate><creator>Rivers, John T.</creator><creator>White, Harvey D.</creator><creator>Cross, David B.</creator><creator>Williams, Barbara F.</creator><creator>Norris, Robin M.</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19900801</creationdate><title>Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking</title><author>Rivers, John T. ; White, Harvey D. ; Cross, David B. ; Williams, Barbara F. ; Norris, Robin M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-ce6bdadfeb8fbc2dec9b0f9eef937a0e47a3c333dab5d0deca09cf3e044d9bc43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1990</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Cardiac Catheterization</topic><topic>Combined Modality Therapy</topic><topic>Coronary Angiography</topic><topic>Coronary Artery Bypass</topic><topic>Creatine Kinase - blood</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Myocardial Infarction - mortality</topic><topic>Myocardial Infarction - physiopathology</topic><topic>Myocardial Infarction - therapy</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>Recurrence</topic><topic>Risk Factors</topic><topic>Smoking - adverse effects</topic><topic>Smoking - epidemiology</topic><topic>Streptokinase - therapeutic use</topic><topic>Survival Rate</topic><topic>Thrombolytic Therapy</topic><topic>Tissue Plasminogen Activator - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rivers, John T.</creatorcontrib><creatorcontrib>White, Harvey D.</creatorcontrib><creatorcontrib>Cross, David B.</creatorcontrib><creatorcontrib>Williams, Barbara F.</creatorcontrib><creatorcontrib>Norris, Robin M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rivers, John T.</au><au>White, Harvey D.</au><au>Cross, David B.</au><au>Williams, Barbara F.</au><au>Norris, Robin M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking</atitle><jtitle>Journal of the American College of Cardiology</jtitle><addtitle>J Am Coll Cardiol</addtitle><date>1990-08-01</date><risdate>1990</risdate><volume>16</volume><issue>2</issue><spage>340</spage><epage>348</epage><pages>340-348</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><coden>JACCDI</coden><abstract>A group of 456 consecutive patients seen ≤ 6 h after the onset of acute myocardial infarction associated with ST segment elevation received thrombolytic therapy and were followed up for 12 months. Intravenous streptokinase was given to 315 patients and recombinant tissue-type plasminogen activator (rt-PA) to 141 patients. Reinfarction rate and risk factors for reinfarction were assessed. Management after thrombolysis was conservative; revascularization procedures were reserved for patients with symptoms refractory to medical therapy or for those with left main coronary artery stenosis. Coronary artery surgery or angioplasty was performed in only 3.7% of patients during the first 30 days after thrombolysis and in only 8.6% by 1 year. Most patients (79%) underwent coronary arteriography.
Twenty-six patients (5.7%) exhibited signs of threatened reinfarction at 1 month after thrombolytic therapy as did 43 patients (9.4%) by 1 year. Reinfarction was prevented in four of these patients by early readministration of thrombolytic therapy. Multivariate analysis of possible risk factors for reinfarction identified at the time of initial infaction showed current cigarette smoking to be the only predictive factor (reinfarction occurred in 12.5% of smokers versus 6.3% of nonsmokers, p = 0.04). A second analysis of risk factors identified 3 weeks after initial infarction, including the severity of residual stenosis at coronary arteriography and exercise test variables, again showed continued cigarette smoking to be the only factor predictive of reinfarction. Twenty percent of patients who continued to smoke developed reinfarction compared with 5.1% of those who stopped (p < 0.01).
Conservative management after thrombolysis with streptokinase or rt-PA results in a reinfarction rate of 8.6% at 1 year. Cigarette smoking predisposes patients to reinfarction; cessation of smoking reduces the risk of reinfarction. The impact of threatened reinfarction can be limited by prompt readministration of thrombolytic therapy.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>2115538</pmid><doi>10.1016/0735-1097(90)90583-B</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0735-1097 |
ispartof | Journal of the American College of Cardiology, 1990-08, Vol.16 (2), p.340-348 |
issn | 0735-1097 1558-3597 |
language | eng |
recordid | cdi_proquest_miscellaneous_79894476 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals |
subjects | Aged Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Cardiac Catheterization Combined Modality Therapy Coronary Angiography Coronary Artery Bypass Creatine Kinase - blood Female Humans Male Medical sciences Middle Aged Multivariate Analysis Myocardial Infarction - mortality Myocardial Infarction - physiopathology Myocardial Infarction - therapy Pharmacology. Drug treatments Randomized Controlled Trials as Topic Recombinant Proteins - therapeutic use Recurrence Risk Factors Smoking - adverse effects Smoking - epidemiology Streptokinase - therapeutic use Survival Rate Thrombolytic Therapy Tissue Plasminogen Activator - therapeutic use |
title | Reinfarction after thrombölytic therapy for acute myocardial infarction followed by conservative management: Incidence and effect of smoking |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A57%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reinfarction%20after%20thromb%C3%B6lytic%20therapy%20for%20acute%20myocardial%20infarction%20followed%20by%20conservative%20management:%20Incidence%20and%20effect%20of%20smoking&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Rivers,%20John%20T.&rft.date=1990-08-01&rft.volume=16&rft.issue=2&rft.spage=340&rft.epage=348&rft.pages=340-348&rft.issn=0735-1097&rft.eissn=1558-3597&rft.coden=JACCDI&rft_id=info:doi/10.1016/0735-1097(90)90583-B&rft_dat=%3Cproquest_cross%3E79894476%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=79894476&rft_id=info:pmid/2115538&rft_els_id=073510979090583B&rfr_iscdi=true |